Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Dr Alike van der Velden
+31 (0)631118081
a.w.vandervelden@umcutrecht.nl


Ms Chanelle Wigger
+31 6 5017 7196
chanelle.wigger@ecraid.eu


Ms Jeri Nijland
+31 (0)6 3111787
jeri.nijland@ecraid.eu


Ms Ilse Rietveld
+31 (0)631118658
Ilse.rietveld@ecraid.eu


More information about this study, what is involved and how to take part can be found on the study website.

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care
Back

Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care

Recruiting

Open to: All Genders

Age: Adult

Utrecht Würzburg Limoges Antwerp Antwerp Antwerp Antwerp Berchem Berchem Antwerp Antwerp Antwerp Turnhout Galway Galway Galway Ballina Tramore bialystok Bialystok Bialystok Bialystok Bialystok Bialystok Tarragona El Prat de Llobregat Fluvià Mataró Barcelona Tblisi Oxford

Medical Conditions

Reducing illness duration, complications, and possibly transmission of COVID-19 (SARS-CoV-2 infection) and other respiratory pathogens

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Most people with COVID-19 and COVID-like illness do not become seriously ill. Some people, however, do go on to have more serious symptoms and may even need to be admitted to hospital. The aim of this study is to investigate the effectiveness and safety of medicinal products to treat COVID-19 and COVID-like illness in adult patients across Europe. This study will investigate whether the medicinal products help patients to recover patients faster, reduce the severity of the symptoms, reduce complications that require treatment in hospital, and prevent spread to family members/housemates.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

03 Oct 2024 31 Dec 2025

Participants will be randomly allocated to receive either usual care alone or an investigational product, a placebo or a comparator product in addition to usual care.
Participants allocated to the usual care group will receive usual clinical care. Participants allocated to usual care + nitric oxide nasal spray will receive nitric oxide nasal spray (NONS) administered intranasally (into the nose) in addition to usual care, six times per day [two sprays per nostril, equivalent to 0.45 ml volume total per dose (four sprays)], for 7 days.
Participants allocated to usual care + saline nasal spray will receive a saltwater solution administered intranasally in addition to usual care, six times per day [two sprays per nostril, equivalent to 0.45 ml volume total per dose (four sprays)], for 7 days. The duration of the study for each participant is 6 months. Participants will be monitored daily for their acute symptoms for 28 days with a diary. They will receive a phone call between 28 days and 35 days in case data capture is not complete. Longer-term follow-up will be at 3 and 6 months by phone calls or electronic questionnaire. A combined throat/nose swab will be taken at the start of the study and on days 4, 7 and 14.


Patients aged 18 years or over and experiencing symptoms of a COVID-19 or COVID-like illness, presenting to primary care with COVID-19 and COVID-like-illness in Belgium, France, Germany, Ireland, Poland, Spain and the UK

You can take part if:



You may not be able to take part if:


A potential participant who meets any of the following criteria will be excluded from participation in ECRAID-Prime (there can be additional intervention-specific exclusion criteria). 1. Requiring admission to the hospital on the day of screening, or inclusion2. Known allergies or hypersensitivities to any of the components used in the formulation of the investigational product, or the control product3. Any disease, condition, or disorder that precludes participation in the trial, in the opinion of the person checking eligibility and taking consent4. Any planned major surgery in the next 28 days5. Currently participating in a trial of an investigational product


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University Medical Center Utrecht
    Heidelberglaan 100
    Utrecht
    3584 CX
  • Universitätsklinikum Würzburg
    Josef-Schneider-Straße 2 // Haus D7
    Würzburg
    97080
  • Centre d’Investigation Clinique (CIC) CHU de Limoges
    2 Avenue Martin Luther King
    Limoges
    87042
  • WGC ‘t Spoor
    Kwekerijstraat 75, Borgerhout
    Antwerp
    2140
  • Huisartsenpraktijk Zwaantjes
    Antwerpsesteenweg 454, Hoboken
    Antwerp
    2660
  • wijkgezondheidscentrum De Vlier
    Truweelstraat 114, Sint-Niklaas
    Antwerp
    9100
  • Huisartsenpraktijk Brig
    Robert Vekemansplein 3 bus 1, Boom
    Antwerp
    2850
  • Huisartsen De Poort
    Grotesteenweg 186, Berchem
    Berchem
    2600
  • huisartsen Wolvenberg
    Vredestraat 93
    Berchem
    2600
  • praktijkhuis de Grote Rivier
    Lanteernhofstraat 106, Deurne
    Antwerp
    2100
  • Villa Medica
    Hoek 15-17, Rijkevorstel
    Antwerp
    2310
  • Huisartsengroep Lange Leem
    Lange Leemstraat 385
    Antwerp
    2018
  • Huisartsenpraktijk Begijnenstraat
    Begijnenstraat 44
    Turnhout
    2300
  • Crescent medical centre
    1 The Crescent
    Galway
    H91 E7FP
  • Heights Medical Centre
    Castlelawn Heights, Coolough Road, Co. Galway
    Galway
    H91YR1X
  • Main Street Clinic
    Main street Loughrea
    Galway
    H62 X252
  • Moyview Family Practice
    Dillon Terrace, Ballina, Co. Mayo
    Ballina
    F26 R9V2
  • Tramore Medical Centre
    Summerhill Centre, Tramore, Co. Waterford
    Tramore
    X91 X90F
  • Akademicka Praktyka Medycyny Rodzinnej Bielska
    15-269 Bialystok, ul. Mazowiecka 33
    bialystok
    15-269
  • Medimed
    ul.Tuwima 1/2 lok. 2
    Bialystok
    15-746
  • Spółka cywilna SILOE Katarzyna Jachimowicz
    ul. W Raginisa 87/2
    Bialystok
    15-156
  • Poradnia Lekarza Rodzinnego Joanna Redźko-Baszun
    ul. Klepacka 4
    Bialystok
    15-634
  • NZOZ „Poradnia Rodzinna” Agnieszka Gosk
    ul. Ks. St. Andrukiewicza 4 lok 3u
    Bialystok
    15-204
  • Centrum Medyczne Kleosin Wieliczko
    ul. Zambrowska 14
    Bialystok
    16-001
  • Centro de Atencion Primaria Jaume 1
    Carrer D/ Felip Pedrell, 2.
    Tarragona
    43005
  • Centro de Atencion Primaria 17 de setembre
    Carrer d'Empúries, S/N
    El Prat de Llobregat
    08820
  • Centro de Atencion Primaria Sant Martí de Provençals
    Fluvià, 211
    Fluvià
    08020
  • Centro de Atencion Primaria Maresme
    Camí del Mig. 36
    Mataró
    08303
  • Equip D'atencio Primaria Barcelona Sardenya S.L.P.
    Carrer Sardenya 466
    Barcelona
    08025
  • Medcapital Gldani
    138 A. Tsereteli Avenue
    Tblisi
    0119
  • Nuffield Department of Primary Care Health Sciences, University of Oxford
    Gibson Building 1st floor Radcliffe Observatory Quarter Woodstock Road
    Oxford
    OX2 6GG

The overall benefits for participants in the intervention group are related to the prevention or treatment effects of the study drug on their COVID-19 or COVID-like illness. Taking part in the study can have possible disadvantages. Participants may experience side effects from the medicinal product. There may be a brief period of discomfort from (self-)taking the combined throat/nose swabs. Taking part in the study will take up some of the time of the participant.

Ms Jeri Nijland
+31 (0)6 3111787
jeri.nijland@ecraid.eu


Ms Chanelle Wigger
+31 6 5017 7196
chanelle.wigger@ecraid.eu


Ms Ilse Rietveld
+31 (0)631118658
Ilse.rietveld@ecraid.eu


Dr Alike van der Velden
+31 (0)631118081
a.w.vandervelden@umcutrecht.nl



More information about this study, what is involved and how to take part can be found on the study website.


The study is sponsored by University Medical Center Utrecht and funded by European Union.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN55471843

Or CPMS 58185

Last updated 04 November 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top